ES2524724T3 - Método para preparar 3alfa-hidroxi,3beta-metil-5alfa-pregnán-20-ona (ganaxolona) - Google Patents
Método para preparar 3alfa-hidroxi,3beta-metil-5alfa-pregnán-20-ona (ganaxolona) Download PDFInfo
- Publication number
- ES2524724T3 ES2524724T3 ES10808696.8T ES10808696T ES2524724T3 ES 2524724 T3 ES2524724 T3 ES 2524724T3 ES 10808696 T ES10808696 T ES 10808696T ES 2524724 T3 ES2524724 T3 ES 2524724T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- titanium
- inert solvent
- halide
- methylating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 title abstract description 5
- 229950006567 ganaxolone Drugs 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title abstract 3
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 abstract description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- XMRPGKVKISIQBV-BJMCWZGWSA-N 5alpha-pregnane-3,20-dione Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 XMRPGKVKISIQBV-BJMCWZGWSA-N 0.000 abstract description 3
- 229910003074 TiCl4 Inorganic materials 0.000 abstract description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 abstract description 2
- 239000012442 inert solvent Substances 0.000 abstract 8
- -1 methyl lithium halide Chemical class 0.000 abstract 8
- 239000012022 methylating agents Substances 0.000 abstract 7
- 125000002524 organometallic group Chemical group 0.000 abstract 7
- GNLJBJNONOOOQC-UHFFFAOYSA-N $l^{3}-carbane;magnesium Chemical compound [Mg]C GNLJBJNONOOOQC-UHFFFAOYSA-N 0.000 abstract 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052742 iron Inorganic materials 0.000 abstract 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 abstract 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract 1
- DNEWOQIRIUNXCU-UHFFFAOYSA-M CCO[Ti](C)(Cl)OCC Chemical compound CCO[Ti](C)(Cl)OCC DNEWOQIRIUNXCU-UHFFFAOYSA-M 0.000 abstract 1
- ITJHDXSUEINCDE-UHFFFAOYSA-N CCO[Ti](C)(OCC)OCC Chemical compound CCO[Ti](C)(OCC)OCC ITJHDXSUEINCDE-UHFFFAOYSA-N 0.000 abstract 1
- KFKFCEOMOZCKGN-UHFFFAOYSA-M C[Fe]Cl Chemical compound C[Fe]Cl KFKFCEOMOZCKGN-UHFFFAOYSA-M 0.000 abstract 1
- UHBKEKFHZYFRRU-UHFFFAOYSA-N C[Ti](C)(C)C Chemical compound C[Ti](C)(C)C UHBKEKFHZYFRRU-UHFFFAOYSA-N 0.000 abstract 1
- ZSURQIOGCDFZDR-UHFFFAOYSA-M C[Ti](C)(C)Cl Chemical compound C[Ti](C)(C)Cl ZSURQIOGCDFZDR-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 abstract 1
- XWMCJIOSNAXGAT-UHFFFAOYSA-L [Cl-].[Cl-].C[Ti+2]C Chemical compound [Cl-].[Cl-].C[Ti+2]C XWMCJIOSNAXGAT-UHFFFAOYSA-L 0.000 abstract 1
- DGXOWMLKUUUVMZ-UHFFFAOYSA-K [Cl-].[Cl-].[Cl-].[Ti+3]C Chemical compound [Cl-].[Cl-].[Cl-].[Ti+3]C DGXOWMLKUUUVMZ-UHFFFAOYSA-K 0.000 abstract 1
- SDDQYJUEVKDWCP-UHFFFAOYSA-N carbanide;iron(2+) Chemical group [CH3-].[CH3-].[Fe+2] SDDQYJUEVKDWCP-UHFFFAOYSA-N 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 239000010936 titanium Substances 0.000 abstract 1
- 229910052719 titanium Inorganic materials 0.000 abstract 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 10
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 10
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 2
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 description 2
- 229950007402 eltanolone Drugs 0.000 description 2
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000556679 Pholis Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910000856 hastalloy Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23355309P | 2009-08-13 | 2009-08-13 | |
| US233553P | 2009-08-13 | ||
| PCT/US2010/045176 WO2011019821A2 (en) | 2009-08-13 | 2010-08-11 | METHOD FOR MAKING 3α-HYDROXY, 3β- METHYL-5α-PREGNAN-20-ONE (GANAXOLONE) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2524724T3 true ES2524724T3 (es) | 2014-12-11 |
Family
ID=43586809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10808696.8T Active ES2524724T3 (es) | 2009-08-13 | 2010-08-11 | Método para preparar 3alfa-hidroxi,3beta-metil-5alfa-pregnán-20-ona (ganaxolona) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8362286B2 (OSRAM) |
| EP (1) | EP2464653B1 (OSRAM) |
| JP (1) | JP5745517B2 (OSRAM) |
| KR (1) | KR101778603B1 (OSRAM) |
| CN (1) | CN102549007B (OSRAM) |
| AU (1) | AU2010282570B2 (OSRAM) |
| BR (1) | BR112012003085B1 (OSRAM) |
| CA (1) | CA2769820C (OSRAM) |
| EA (1) | EA024269B1 (OSRAM) |
| ES (1) | ES2524724T3 (OSRAM) |
| IL (1) | IL217857A (OSRAM) |
| MX (1) | MX2012001728A (OSRAM) |
| NZ (1) | NZ597940A (OSRAM) |
| WO (1) | WO2011019821A2 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1959966B1 (en) | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Ganaxolone formulations and methods for the making and use thereof |
| US9629853B2 (en) | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| CZ305837B6 (cs) * | 2015-02-25 | 2016-03-30 | Vysoká škola chemicko - technologická v Praze | (3α,5β,20S)-3-Nitrooxy-pregnan-20-karboxylová kyselina |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| CN106366149B (zh) * | 2016-08-09 | 2018-01-23 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮分散片的有关物质及其分析检测方法 |
| CN106279326A (zh) * | 2016-08-09 | 2017-01-04 | 南京臣功制药股份有限公司 | 一种醋酸甲羟孕酮胶囊的有关物质及其分析检测方法 |
| MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| IT201800009683A1 (it) * | 2018-10-22 | 2020-04-22 | Ind Chimica Srl | Processo per la preparazione di 3α-idrossi-5α-pregnan-20-one (brexanolone) |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS |
| MX2022006014A (es) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa. |
| IT202000021316A1 (it) * | 2020-09-09 | 2022-03-09 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| EP0701444B1 (en) * | 1993-05-24 | 2010-04-07 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| FR2720747B1 (fr) * | 1994-06-02 | 1996-07-12 | Roussel Uclaf | Nouveau procédé de préparation d'un stéroïde 16béta-méthyl et nouveaux intermédiaires. |
| BR9509764A (pt) * | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| US20060009432A1 (en) * | 2004-07-09 | 2006-01-12 | Roger Whiting | Use of neurosteroids to treat neuropathic pain |
| EP1959966B1 (en) * | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Ganaxolone formulations and methods for the making and use thereof |
-
2010
- 2010-08-11 ES ES10808696.8T patent/ES2524724T3/es active Active
- 2010-08-11 JP JP2012524841A patent/JP5745517B2/ja active Active
- 2010-08-11 CN CN201080035660.3A patent/CN102549007B/zh active Active
- 2010-08-11 NZ NZ597940A patent/NZ597940A/xx unknown
- 2010-08-11 EA EA201270241A patent/EA024269B1/ru active IP Right Revival
- 2010-08-11 AU AU2010282570A patent/AU2010282570B2/en active Active
- 2010-08-11 KR KR1020127006429A patent/KR101778603B1/ko active Active
- 2010-08-11 BR BR112012003085-0A patent/BR112012003085B1/pt active IP Right Grant
- 2010-08-11 WO PCT/US2010/045176 patent/WO2011019821A2/en not_active Ceased
- 2010-08-11 EP EP10808696.8A patent/EP2464653B1/en active Active
- 2010-08-11 US US12/854,226 patent/US8362286B2/en active Active
- 2010-08-11 CA CA2769820A patent/CA2769820C/en active Active
- 2010-08-11 MX MX2012001728A patent/MX2012001728A/es active IP Right Grant
-
2012
- 2012-01-31 IL IL217857A patent/IL217857A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL217857A (en) | 2016-03-31 |
| BR112012003085A2 (pt) | 2020-12-01 |
| KR101778603B1 (ko) | 2017-09-14 |
| JP2013501803A (ja) | 2013-01-17 |
| EA024269B1 (ru) | 2016-09-30 |
| US20110040112A1 (en) | 2011-02-17 |
| EP2464653A4 (en) | 2013-01-16 |
| JP5745517B2 (ja) | 2015-07-08 |
| EP2464653B1 (en) | 2014-10-22 |
| CN102549007A (zh) | 2012-07-04 |
| AU2010282570B2 (en) | 2014-04-24 |
| HK1171761A1 (en) | 2013-04-05 |
| AU2010282570A1 (en) | 2012-02-23 |
| WO2011019821A2 (en) | 2011-02-17 |
| NZ597940A (en) | 2013-03-28 |
| IL217857A0 (en) | 2012-03-29 |
| CA2769820A1 (en) | 2011-02-17 |
| EA201270241A1 (ru) | 2013-09-30 |
| US8362286B2 (en) | 2013-01-29 |
| CA2769820C (en) | 2017-06-27 |
| EP2464653A2 (en) | 2012-06-20 |
| BR112012003085B1 (pt) | 2021-06-01 |
| KR20120084715A (ko) | 2012-07-30 |
| WO2011019821A3 (en) | 2011-06-16 |
| MX2012001728A (es) | 2012-06-01 |
| CN102549007B (zh) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2524724T3 (es) | Método para preparar 3alfa-hidroxi,3beta-metil-5alfa-pregnán-20-ona (ganaxolona) | |
| ES2487190T3 (es) | Procedimiento de producción de clorhidrato de prasugrel de alta pureza | |
| EP3826997B1 (en) | Process and intermediates for the preparation of bilastine | |
| CN103339113B (zh) | 吡唑羧酸酰胺的制备方法 | |
| JP5784336B2 (ja) | 化合物、及びその製造方法、並びにリン酸オセルタミビルの製造方法 | |
| CN106631885B (zh) | 一种制备4-甲醛肟基苯甲酸酯类衍生物的方法 | |
| ES2741505T3 (es) | Procedimiento para la preparación de acetato de abiraterona y sus productos intermedios | |
| CN106957255A (zh) | 一种(R)‑N‑Boc‑5‑溴‑1‑甲基异吲哚啉及其制备方法和应用 | |
| Uccello et al. | The synthesis of C-13 functionalized pleuromutilins via C–H amidation and subsequent novel rearrangement product | |
| Liu et al. | Regio-and stereoselective synthesis of functionalized allylic fluorides via palladium-catalyzed three-component tandem carbofluorination of allenes | |
| Zhu et al. | Unusual reactivity of fluoro-enolates with dialkyl azodicarboxylates: Synthesis of isatin-hydrazones | |
| US9150524B2 (en) | Pure intermediate | |
| CN105985329B (zh) | 一种新的泊沙康唑化合物制备方法 | |
| CN107629107B (zh) | 一种醋酸乌利司他的合成方法 | |
| CN101134740A (zh) | 一种酮咯酸氨丁三醇关键中间体苯甲酰吡咯的合成方法 | |
| CN115572231B (zh) | 一种双环[1.1.1]戊烷-1,3-二胺的盐的合成方法 | |
| CN111440126B (zh) | 一种米拉贝隆的制备方法 | |
| US10626102B2 (en) | Process for the synthesis of efinaconazol | |
| JP5127114B2 (ja) | Ｃｆ３−ｃｈｆ−ｃｆ２−ｎｒ２合成方法 | |
| CN107880080A (zh) | 一种2,3,4,6‑四苄基‑d‑吡喃葡萄糖的合成方法 | |
| JP4356296B2 (ja) | ２−ナフトール誘導体の製造方法 | |
| Smolobochkin et al. | Reaction of 4-chloro-and 4-bromobenzene-1, 3-diols with 1-alkyl-3-(4, 4-diethoxybutyl) ureas in the presence of trifluoroacetic acid | |
| CN111116436B (zh) | 一种含1,4-萘醌结构的硫醚类化合物的合成方法 | |
| CN109232531B (zh) | 一种卡比替尼的制备方法 | |
| CN109369576B (zh) | 一种合成3-甲基氧杂环丁烷-3-(4-硝基苯基)碳酸酯的方法 |